Renoprotective effects of dulaglutide, a GLP-1 agonist, involving regulation of epithelial-mesenchymal transition in patients with type 2 diabetes and diabetic kidney disease.

Jiang D, Meng F, Chou X, Shen J, Liu M

International journal of clinical pharmacology and therapeutics1 Apr 2025

PMID39790030DOI10.5414/cp204632PepBankPUB-39790030

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanObservational studyEfficacy outcome
In patients with diabetes and DKD, dulaglutide was linked to lower UACR changes than control at 6 months.
In plain wordsIn patients with diabetic kidney disease, dulaglutide was linked to lower urine albumin changes than control at 6 months.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseUACR at 6 months
Study
n = 135
Comparator
Hypoglycemic agents without GLP-1 receptor agonists
Analysis
Primary
Outcome group
Kidney function · Kidney and urinary
Studied dose
0.75 - 1.5 mg once weekly · 12 monthsAs given in this study (human).
Source sentences
Summary
UACR changes in the intervention group compared to the control group were significantly lower (p < 0.01 at 6 months and p < 0.05 at 12 months).
3 context sentences(design, population, supporting numbers)
Summary · context
were prescribed dulaglutide at a dose rate of 0.75 - 1.5 mg once weekly (intervention group; n = 70).
Summary · context
Patients receiving hypoglycemic agents other than glucagon-like peptide-1 (GLP-1) receptor agonists and who were not prescribed dulaglutide constituted the control group (n = 65).
Summary · context
Observations/outcomes: The primary outcome was a change in the UACR and biomarkers of epithelial-mesenchymal transition (EMT) determined after 12 months of intervention treatment.
Report a problemFND-3979003001
02HumanObservational studyEfficacy outcome
In patients with diabetes and DKD, dulaglutide was linked to lower UACR changes than control at 12 months.
In plain wordsIn patients with diabetic kidney disease, dulaglutide was linked to lower urine albumin changes than control at 12 months.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseUACR at 12 months
Study
n = 135
Comparator
Hypoglycemic agents without GLP-1 receptor agonists
Analysis
Primary
Outcome group
Kidney function · Kidney and urinary
Studied dose
0.75 - 1.5 mg once weekly · 12 monthsAs given in this study (human).
Source sentences
Summary
UACR changes in the intervention group compared to the control group were significantly lower (p < 0.01 at 6 months and p < 0.05 at 12 months).
3 context sentences(design, population, supporting numbers)
Summary · context
were prescribed dulaglutide at a dose rate of 0.75 - 1.5 mg once weekly (intervention group; n = 70).
Summary · context
Patients receiving hypoglycemic agents other than glucagon-like peptide-1 (GLP-1) receptor agonists and who were not prescribed dulaglutide constituted the control group (n = 65).
Summary · context
Observations/outcomes: The primary outcome was a change in the UACR and biomarkers of epithelial-mesenchymal transition (EMT) determined after 12 months of intervention treatment.
Report a problemFND-3979003002
03HumanObservational studyMechanism
In patients with diabetes and DKD, dulaglutide was linked to increased E-cadherin.
In plain wordsIn patients with diabetic kidney disease, dulaglutide was linked to increased E-cadherin.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseE-cadherin
Study
n = 135
Analysis
Primary
Outcome group
Kidney function · Kidney and urinary
Studied dose
0.75 - 1.5 mg once weekly · 12 monthsAs given in this study (human).
Source sentences
Summary
Dulaglutide significantly increased the epithelial marker E-cadherin and inhibited the mesenchymal marker periostin.
3 context sentences(design, population, supporting numbers)
Summary · context
were prescribed dulaglutide at a dose rate of 0.75 - 1.5 mg once weekly (intervention group; n = 70).
Summary · context
Patients receiving hypoglycemic agents other than glucagon-like peptide-1 (GLP-1) receptor agonists and who were not prescribed dulaglutide constituted the control group (n = 65).
Summary · context
Observations/outcomes: The primary outcome was a change in the UACR and biomarkers of epithelial-mesenchymal transition (EMT) determined after 12 months of intervention treatment.
Report a problemFND-3979003005
04HumanObservational studyMechanism
In patients with diabetes and DKD, dulaglutide was linked to inhibited periostin.
In plain wordsIn patients with diabetic kidney disease, dulaglutide was linked to reduced periostin.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreasePeriostin
Study
n = 135
Analysis
Primary
Outcome group
Kidney function · Kidney and urinary
Studied dose
0.75 - 1.5 mg once weekly · 12 monthsAs given in this study (human).
Source sentences
Summary
Dulaglutide significantly increased the epithelial marker E-cadherin and inhibited the mesenchymal marker periostin.
3 context sentences(design, population, supporting numbers)
Summary · context
were prescribed dulaglutide at a dose rate of 0.75 - 1.5 mg once weekly (intervention group; n = 70).
Summary · context
Patients receiving hypoglycemic agents other than glucagon-like peptide-1 (GLP-1) receptor agonists and who were not prescribed dulaglutide constituted the control group (n = 65).
Summary · context
Observations/outcomes: The primary outcome was a change in the UACR and biomarkers of epithelial-mesenchymal transition (EMT) determined after 12 months of intervention treatment.
Report a problemFND-3979003006
05HumanObservational studySafety outcome
In patients with diabetes and DKD, gastrointestinal adverse event frequency did not differ significantly between dulaglutide and control.
In plain wordsIn patients with diabetic kidney disease, digestive side effect frequency did not differ significantly between dulaglutide and control.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changeGastrointestinal adverse events
Study
n = 135
Comparator
Hypoglycemic agents without GLP-1 receptor agonists
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
0.75 - 1.5 mg once weekly · 12 monthsAs given in this study (human).
Source sentences
Summary
The frequency of gastrointestinal adverse events in the two groups were not significantly different, and there were no significant increases in the number of hypoglycemic events.
3 context sentences(design, population, supporting numbers)
Summary · context
were prescribed dulaglutide at a dose rate of 0.75 - 1.5 mg once weekly (intervention group; n = 70).
Summary · context
Patients receiving hypoglycemic agents other than glucagon-like peptide-1 (GLP-1) receptor agonists and who were not prescribed dulaglutide constituted the control group (n = 65).
Summary · context
Observations/outcomes: The primary outcome was a change in the UACR and biomarkers of epithelial-mesenchymal transition (EMT) determined after 12 months of intervention treatment.
Report a problemFND-3979003003
06HumanObservational studySafety outcome
In patients with diabetes and DKD, dulaglutide showed no significant increase in hypoglycemic events.
In plain wordsIn patients with diabetic kidney disease, dulaglutide showed no significant increase in low blood sugar events.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changeHypoglycemic events
Study
n = 135
Comparator
Hypoglycemic agents without GLP-1 receptor agonists
Outcome group
Adverse events · Metabolic and weight
Studied dose
0.75 - 1.5 mg once weekly · 12 monthsAs given in this study (human).
Source sentences
Summary
The frequency of gastrointestinal adverse events in the two groups were not significantly different, and there were no significant increases in the number of hypoglycemic events.
3 context sentences(design, population, supporting numbers)
Summary · context
were prescribed dulaglutide at a dose rate of 0.75 - 1.5 mg once weekly (intervention group; n = 70).
Summary · context
Patients receiving hypoglycemic agents other than glucagon-like peptide-1 (GLP-1) receptor agonists and who were not prescribed dulaglutide constituted the control group (n = 65).
Summary · context
Observations/outcomes: The primary outcome was a change in the UACR and biomarkers of epithelial-mesenchymal transition (EMT) determined after 12 months of intervention treatment.
Report a problemFND-3979003004

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:25 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.